


WHAT IS CLAIMED IS:

1. A therapeutic agent for osteoporosis comprising an active ingredient of quercetin derivatives represented by the following general formula(I) and a pharmaceutically acceptable carrier:



wherein,

R₁ is gentiotriose, glucopyranose, O-arabinofuranose, O-diglucopyranose, O-galactopyranose, O-galactoside-gallate, O-gentiobiose, O-glucopyranose, O-glucuronide, O-neohesperidose, O-rhamnopyranose, O-rutinoside, O-sophorose, O-xylopyranose, OCH₃, OH, rhamnogentiobiose, rhamnoglucose or sulfate;

R₂ is OH or O-glucopyranose;

R₃ is OCH₃, OH, O-glucopyranose, O-glucuronopyranose or glucopyranose;

R₄ is OCH₃ or OH; and,

R₅ is OCH₃, OH, O-glucopyranose or O-glucose.

2. The therapeutic agent for osteoporosis of claim 1, wherein the quercetin derivatives are compounds represented by general formula(I) whose R₂, R₃, R₄ and R₅ are -OH as followings: quercetin, avicularoside, guaijaverin, hyperoside, isohyperoside, isoquercitrin, multinoside A, multinoside A acetate, quercitrin, rutin, quercetin-3-O-

(2"-O-β-D-glucopyranosyl)-α-L-rhamnopyranoside, quercetin-3-O-(6"-O-galloyl)-glucopyranoside, quercetin-3-O-(6'"-O-p-coumaroyl-β-D-glucopyranosyl-(1-2)-α-L-rhamnopyranoside), quercetin-3-O-D-glucopyranosyl-(1-6)-β-D-glucopyranosyl-(1-4)-α-L-rhamnopyranoside, quercetin-3-O-[2"-O-6'"-O-p-(7'''-O-β-D-glucopyranosyl)coumaroyl-β-D-glucopyranosyl]-α-L-rhamnopyranoside, quercetin-3-O-[6'"-p-coumaroyl-β-D-glucopyranosyl-β-(1-4)-rhamnopyranoside], quercetin-3-O-[α-L-rhamnopyranosyl(1-2)-α-L-rhamnopyranosyl-(1-6)-β-D-glucopyranoside], quercetin-3-O-[α-rhamnopyranosyl(1-4)α-L-rhamnopyranosyl(1-6)β-D-galactopyranoside], quercetin-3-O-[α-rhamnopyranosyl-(1-2)]-β-glucopyranosyl-(1-6)-β-D-galactopyranoside, quercetin-3-O-[α-rhamnopyranosyl-(1-4)-α-rhamnopyranosyl-(1-6)-β-galactopyranoside], quercetin-3-O-α-L-rhamnopyranosyl-(1-2)-β-D-galactopyranoside, quercetin-3-O-β-D-diglucopyranoside, quercetin-3-O-β-D-galactoside-2"-gallate, quercetin-3-O-β-D-glucopyranoside-(1-6)-β-D-galactopyranoside, quercetin-3-O-β-D-glucopyranosyl-(1-3)-α-L-rhamnopyranosyl-(1-6)-β-D-galactopyranoside, quercetin-3-O-β-D-glucuronide, quercetin-3-O-β-D-xylopyranoside, quercetin-3-O-diglucospyranoside, quercetin-3-O-gentiobioside, quercetin-3-O-glucopyranosylgalactopyranoside, quercetin-3-O-neohesperidoside, quercetin-3-gentiotrioside, quercetin-3-methyl ether, quercetin-3-rhamnogentiobioside, quercetin-3-rhamnoglucoside, or quercetin-3-sulfate.

3. The therapeutic agent for osteoporosis of claim 1, wherein the quercetin derivatives are compounds represented by general formula(I) whose R₁ is -OH and three functional groups out of R₂, R₃, R₄ and R₅ are -OH as followings: isorhamnetin, quercimeritrin, rhamnetin, quercetin-5-O-β-D-glucopyranoside, quercetin-7-O-β-D-glucuronopyranoside or spireaoside.

4. The therapeutic agent for osteoporosis of claim 1,

wherein the quercetin derivatives are compounds represented by general formula(I) whose three functional groups out of R₁, R₂, R₃, R₄ and R₅ are -OH as followings: rhamnazin, quercetin-3',4'-di-methyl ether, quercetin-3,3'-dimethyl ether, quercetin-3,7-dimethyl ether, quercetin-3-O-[2"-O-(6"-O-p-coumaroyl)-β-D-glucopyranosyl]-α-L-rhamnopyranosyl-7-O-β-D-glucopyranoside, quercetin-3-O-[2"-O-6"-O-p-(7"-O-β-D-glucopyranosyl)coumaroyl-β-D-glucopyranosyl]-α-L-rhamnopyranoside-7-O-β-D-glucopyranoside, quercetin-3-O-rutinoside-7-O-β-D-glucopyranoside, quercetin-3-O-α-L-arabinopyranosyl-7-O-β-D-glucopyranoside, quercetin-7-O-β-D-glucopyranoside-3-O-sophoroside, quercetin-3-O-galactopyranosyl-7-O-diglucopyranoside, quercetin-3-O-glucopyranosyl-7-O-diglucopyranoside, quercetin-3,7-diglucopyranoside, quercetin-3-gentiobiosyl-7-glucopyranoside or quercetin-3,4'-di-O-β-D-glucopyranoside.

5. The therapeutic agent for osteoporosis of claim 1, wherein the quercetin derivative is quercetin-3,4',7-trimethyl ether or quercetin-3,3',4',7-tetramethyl ether.

6. The therapeutic agent for osteoporosis of claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of polyvinylpyrrolidone and hydroxypropylcellulose.

7. The therapeutic agent for osteoporosis of claim 1, wherein the pharmaceutically acceptable carrier is a disintegrating agent selected from the group consisting of calcium carboxymethylcellulose and sodium glycolate starch.

8. The therapeutic agent for osteoporosis of claim 1, wherein the pharmaceutically acceptable carrier is a diluting agent selected from the group consisting of corn starch, lactose, soybean oil, crystalline cellulose and mannitol.

9. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
lubricating agent selected from the group consisting of
magnesium stearate and talc.

10. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
sweetener selected from the group consisting of sucrose,
fructose, sorbitol and aspartame.

11. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
stabilizing agent selected from the group consisting of
sodium carboxymethylcellulose, α - or β -cyclodextrin,
vitamin C, citric acid and white wax.

12. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
preservative selected from the group consisting of
paraoxymethylbenzoate, paraoxypropylbenzoate and sodium
benzoate.

13. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is an
aromatic selected from the group consisting of
ethylvanillin, masking flavor, flavonomenthol and herb
flavor.

14. The therapeutic agent for osteoporosis of claim 1,
wherein the therapeutic agent is a pharmaceutical
formulation for oral or parenteral administration selected
from the group consisting of tablets, capsules, soft
capsules, liquids, ointments, pills, powders, suspensions,
emulsions, syrups, suppositories and injections.

15. The therapeutic agent for osteoporosis of claim 1
which further comprises calcium or vitamin D₃.

5

10

15

20

25

30

35